Overview

A Controlled Trial of Erenumab in Migraine Prevention

Status:
Completed
Trial end date:
2020-11-25
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Erenumab